HeraMED Limited Overview
HeraMED is a micro-cap medical data and technology company building a hybrid, digital-first model of maternity care. Its stack combines HeraBEAT, a clinically validated, smartphone-connected ultrasound fetal Doppler cleared by the US FDA and approved by Australia's TGA as a Class IIb device, with HeraCARE, a cloud SaaS platform providing patient companion apps, clinician dashboards, configurable prenatal and postpartum care plans, remote patient monitoring, telehealth and EMR integration. After a decade selling devices and small pilots across Israel, Australia, the US and Brazil, the company reset in 2024 under new leadership toward a US health-system SaaS model priced per mother per 12 months. Late 2025 brought two validating relationships — a commercial agreement with Philips' US subsidiary Telcare Medical Supply and a pilot with Florida's Lee Health — and in September 2026 Lee Health approved full commercial deployment, generating an initial US$317,200 statement of work. Revenue remains sub-A$0.5M annually and the business is funded by equity.
Company's own description (FY2025 Annual Report, Directors' Report – Principal Activities). HeraMED describes itself as an innovative medical data and technology company leading the digital transformation of maternity care by reshaping the prenatal and postpartum experience through a hybrid maternity care platform. It says its proprietary platform uses hardware and software to reshape the doctor–patient relationship, built on its clinically validated in-home fetal and maternal heart-rate monitor (HeraBEAT), cloud computing, artificial intelligence and big data. HeraCARE is positioned as a fully integrated maternal-health ecosystem intended to deliver better care at lower cost, keep expectant mothers engaged and informed, allow clinicians to deliver high-quality care, and enable early detection of potential risks. Since 2025 the company increasingly frames its scope as "women's health more broadly", starting with maternity.
Independent characterisation. HeraMED is best understood as an early-commercial vertical remote-patient-monitoring (RPM) and care-management SaaS vendor for obstetrics, with a proprietary device that acts as the differentiating data-capture endpoint. Economically, it is not yet a device company (device revenue was only A$19,571 in FY2025) nor a scaled SaaS company (software revenue A$273,809). Its commercial engine is enterprise sales into US health systems, with channel leverage sought through Philips. The 2025 accounting decisions — writing inventory to nil because devices will be bundled into SaaS arrangements, and impairing all capitalised HeraBEAT development costs — formally signal that the device is now treated as an enabler of platform subscriptions rather than a standalone product.
Business model and revenue model
| Revenue stream | Mechanics (per FY2025 accounting policies and Lee Health SOW) | FY2025 (AUD) | FY2024 (AUD) |
|---|---|---|---|
| Software / platform (HeraCARE subscriptions; HeraBEAT app subscriptions) | Subscription fees for platform access recognised straight-line over contract term; HeraBEAT device plus app treated as a single integrated performance obligation recognised over time | 273,809 | 225,032 |
| Sale of goods (devices, kits) | Historically point-in-time device sales; from FY2025 devices increasingly bundled into SaaS arrangements | 19,571 | 139,296 |
| Government grant income (other income) | Grants including RMIT / Digital Health CRC research funding | 138,225 | 116,899 |
| Total "revenues from ordinary activities" | As reported in Appendix 4E | 431,605 | 481,227 |
Commercial pricing model (Lee Health, 16 Sep 2026). HeraCARE is licensed on a 12-month per-mother term. A bundle comprises the platform licence, a maternity monitoring kit (FDA-cleared HeraBEAT plus connected blood-pressure monitor), implementation fees, an Epic EMR integration fee, logistics, and device and application support. Additional cohorts can be ordered in increments of 20, 50, 100 or more. The initial Lee SOW of US$317,200 for 200 mothers implies roughly US$1,586 per mother all-in for the first cohort (analyst calculation; the figure includes one-off implementation and Epic integration fees, so steady-state per-mother pricing will differ and is not disclosed).
Mix assessment. FY2025 sales revenue was approximately 93% software / subscription and 7% goods. Licensing (IP out-licensing) revenue: none disclosed. Services revenue is embedded within SaaS bundles (implementation, support).
Value-chain position
HeraMED designs the HeraBEAT device and HeraCARE software in-house (Israel heritage R&D; technology leadership now under a CTO appointed in 2025). Device manufacturing has historically been outsourced (contract manufacturing; specific manufacturer not publicly disclosed). In the Philips channel, Philips supplies monitoring devices, logistics and technical support while HeraMED supplies the HeraCARE platform — i.e., HeraMED is positioned as the clinical-workflow software layer sitting between the device ecosystem and the health system's EMR (Epic).
Customer types and end-markets
| Customer type | Examples (disclosed) | Status |
|---|---|---|
| US integrated health systems | Lee Health (FL); Broward Health (FL, 2024 two-year agreement) | Lee: commercial deployment from 15 Sep 2026 |
| Channel / strategic partners | Telcare Medical Supply LLC (Philips subsidiary); Telstra Health Smart Marketplace (AU) | Active |
| Australian public hospitals and health services | Gold Coast University Hospital (clinical trial up to 90 pregnancies); Joondalup Health Campus private obstetricians (PHI Research) | Trials / historical |
| Primary-care and shared-care networks | GPEx (South Australia GP Obstetric Shared Care program) | Paid pilot from Jan 2024 |
| Virtual care / femtech providers (US) | e-Lōvu, FemBridge, Wingwomen, Metronomic (LOI) | Mixed; several were MOUs/LOIs |
| Consumers (direct) | Historical HeraBEAT direct-to-consumer and distributor sales (e.g., Germany distributor) | De-emphasised |
End-markets: prenatal care, postpartum care, hypertensive disorders of pregnancy, and (aspirationally) broader women's health pathways. Geographic focus: United States (primary), Australia (secondary, supported by TGA Class IIb status), Europe (HeraMED Europe BV incorporated in Belgium in 2025; commercial activity not yet material).
Strategy
Stated strategy (themes from FY2025 Annual Report and 2026 ASX releases)
"Digital transformation of women's and maternity care": expanding from maternity into women's health more broadly.
US-first commercialisation: the US is described as HeraMED's core strategic and commercial focus (Q2 FY26 4C).
Health-system SaaS with recurring revenue: transition from pilots to recurring platform revenue, validated by Lee Health's 12-month per-mother licence.
Channel leverage: Philips as strategic channel partner; joint business development and coordinated hospital engagement.
"Data-as-an-asset": building a repository of maternal vitals (>200,000 measurements) to power AI predictive models.
Interoperability: embedding HeraCARE inside the clinician's existing EMR (Epic).
Evidence generation: each deployment builds the clinical and economic evidence base.
Target-customer framework (16 Sep 2026)
HeraMED says it is applying a qualification framework to its US pipeline, targeting health systems with: a dedicated maternity / women's-health service; a goal of improving maternal-fetal outcomes; connected hybrid/virtual-care strategic plans; EMR integration and technology capability; and exposure to regional obstetric supply constraints (maternity-care deserts).
Initiatives announced in the last 24 months
| Date | Initiative | Type | Detail / target |
|---|---|---|---|
| Oct 2024 | Cost restructuring | Cost program | Notice-period savings from October 2024; quarterly outflow reduced from >A$1.2M (2024 run-rate implied by A$4.8M annual OCF) to A$0.64M (Q2 FY26). No formal numeric target disclosed |
| Nov 2024 | Metronomic LOI | Partnership (non-binding) | Co-design postpartum care plans; revenue-share model to be agreed |
| 2,024 | Founda Health integration | Platform | Interoperability layer for HeraCARE |
| Jun 2025 | RMIT / Digital Health CRC AI research | R&D / grant | Predictive models for maternity risk |
| 2,025 | Garmin Health collaboration | Partnership | Wearable activity, heart-rate and sleep data into HeraCARE |
| 2,025 | TGA Class IIb for HeraBEAT | Regulatory | Unique Australian home-use position |
| 2,025 | HeraMED Europe BV | Platform investment | European entity in Belgium |
| 2,025 | Executive build-out | Organisation | CGO (US), CTO, CMO |
| Nov 2025 | Philips (Telcare) agreement | Channel | 12-month initial term; expansion under negotiation |
| Nov 2025–Sep 2026 | Lee Health pilot → commercial | Customer | Phase 1 complete Jul 2026; commercial deployment from 15 Sep 2026; US$317,200 initial SOW |
| 2,026 | US Rural Health Transformation Program positioning | Market access | US$50B federal program; joint positioning with Philips |
| 2,026 | Epic integration at Lee Health | Platform | First disclosed Epic integration |
ESG / sustainability commitments: none formally announced beyond RoHS/WEEE compliance.
Medium-term targets and guidance
No quantitative revenue, EBITDA or cash-flow-breakeven guidance has been issued. The FY2025 AR states that disclosing likely developments would cause unreasonable prejudice. The only quantified forward commitments are contract-level: the US$317,200 Lee SOW and the incremental-cohort framework.
Products & Services
All products sit within the single reportable segment.
HeraBEAT (connected fetal and maternal heart-rate monitor)
Description: Medical-grade, clinically validated, smartphone-connected ultrasound fetal Doppler that allows an expectant mother to record fetal heart rate (FHR) and maternal heart rate at home; data synchronise to the HeraBEAT app and into HeraCARE.
Regulatory status: Described by the company as FDA-cleared (16 Sep 2026 announcement). TGA Class IIb approval (2025) — company states it is the only approved remote home-use fetal heart monitor in Australia following TGA's reclassification of consumer fetal dopplers. Compliant with EU RoHS 3 and WEEE directives (FY2025 AR).
Target customer: Health systems and clinicians deploying RPM pathways; historically also consumers via distributors.
Launch / latest version: Original launch year not publicly disclosed in reviewed filings; capitalised development costs (A$3.43M gross) were fully amortised/impaired by 31 Dec 2025. Next-generation devices "EchoBEAT" and an AI analysis system "Orion" appear in aggregator profiles (stoxray, dividend.watch) but are not referenced in FY2024–FY2025 filings; status not publicly disclosed.
Pricing: Not separately disclosed; now bundled into per-mother SaaS kits. In the 2024 Broward agreement, each hardware bundle (HeraBEAT, BP cuff, Bluetooth scale, co-branded bag) was priced at ~US$498 (US$99,600 / 200; analyst calculation).
Accounting: Device and app treated as one integrated performance obligation recognised over time (FY2025 AR note 1(e)).
HeraCARE (digital maternity and women's-health platform)
Description: Cloud-based, HIPAA-compliant SaaS platform comprising a patient companion app, clinician dashboards, configurable and automated notifications, telehealth call and chat, personalised educational content (originally Mayo Clinic-provided), connected-device integrations (HeraBEAT, BP cuffs, scales, Garmin wearables) and analytics.
Care plans deployed at Lee Health: (1) low-risk prenatal care, (2) hypertension in pregnancy, (3) postpartum care, (4) patient engagement.
Interoperability: Epic EMR integration being implemented at Lee Health (2026); broader EMR/EHR interoperability development cited in FY2025 AR; earlier integration work with Founda Health (2024).
AI roadmap (FY2025 AR): predictive modelling for earlier risk identification; AI clinician-support tools to automate documentation; RMIT / Digital Health CRC predictive-model research.
Scale metrics: 3,051 accumulated users and 72,604 measurements (31 Dec 2023); ~3,800 accumulated users and 710 active mothers (30 Sep 2024); >167,000 maternal measurements (Dec 2025 quarter); >200,000 maternal vital measurements (Mar 2026 quarter).
Pricing model: 12-month per-mother licence; bundles orderable in increments of 20/50/100+ (Lee Health, 2026). Historical models included per-pregnancy and per-user-per-month licences (FY2023 AR note 1(l)).
Flagship deployment: Lee Health "Digital Pregnancy Journey Program" — an 11-visit digital-first pathway versus ~15 in-person visits in the traditional model; Phase 1 KPIs: 92% virtual adoption, 100% likelihood to recommend, programme NPS 60, RPM device NPS 75.
HeraCARE Pro / earlier platform variants
- "HeraCARE Pro" was referenced in the Hapvida (Brazil) trial era (ShareCafe); the brand does not appear in FY2024–FY2025 filings. Status: superseded / not publicly disclosed.
Integrated solution with Philips (channel offering)
Description: Joint US offering combining Philips monitoring devices, logistics and technical support (via Telcare Medical Supply LLC) with HeraCARE. Initial 12-month term with renewal option; either party can terminate on 30 business days' notice (ASX 25 Nov 2025). During 2026 the parties progressed to a joint sales strategy and are negotiating an expanded agreement; both are positioning for the US$50B Rural Health Transformation Program.
Pricing / revenue share: Not publicly disclosed.
Services
- Implementation, clinic onboarding, Epic integration, logistics, device and application support — sold within health-system SOWs (Lee Health). Medical advisory / KOL services via PHI Research (Australia, 2024). Revenue not separately disclosed.
Financial Narrative
Income statement — USD block
FY2021 revenue and net loss are from TipRanks (aggregator). FY2022–FY2023 from FY2023 Annual Report.
Income statement — AUD block
FY2023 AUD figures are restated comparatives in the FY2024 Annual Report (revenue A$606,226; loss before finance A$6,669,276; loss A$6,775,173). Cost of sales is not presented as a separate line in the FY2024–FY2025 AUD income statements; gross profit is therefore not disclosed on a like-for-like basis (Simply Wall St reports FY2025 cost of revenue A$381.1k, which corresponds to the inventory impairment rather than a true COGS line).
Margins (analyst calculations on sales revenue)
FY2022–FY2023 computed in USD; FY2024–FY2025 in AUD. FY2023 net margin uses USD figures (AUD-restated basis gives -1118% as well, A$6.78M / A$0.61M).
Revenue CAGR. USD basis FY2021–FY2023: +119% per annum (from a very small, aggregator-sourced base). AUD basis FY2023–FY2025 (sales): -30.4% per annum. Total revenue including grants, AUD FY2023–FY2025: -15.6% per annum.
Balance sheet
USD block (USD thousands):
AUD block (AUD thousands):
Notes: FY2023 AUD cash is the FY2024 cash-flow opening balance; FY2023 AUD equity is the restated 1 January 2024 balance. H1 2026 from Half-Year Report. FY2025 accumulated losses fell despite the loss because A$6.09M of expired option reserves and the A$0.19M predecessor-accounting reserve were transferred into accumulated losses (FY2025 AR statement of changes in equity). The IIA liability is a contingent, royalty-linked obligation (USD 188,000 carrying value at 31 Dec 2025) measured at fair value with a 20% discount rate; it is debt-like but not a borrowing.
Cash flow
USD block (USD thousands):
AUD block (AUD thousands):
Quarterly cash trajectory (Appendix 4C, AUD thousands):
The December 2025 quarter outflow was described by the company as the lowest since June 2020. The June 2026 quarter outflow was 25% lower than March. The FY2025 cash-flow statement records nil "receipts from customers" against A$293k of recognised revenue; this reflects the unwinding of A$235,250 of contract liabilities (cash received in prior periods, e.g., Broward upfront payments) plus a A$94,945 doubtful-debt provision.
Ratios (analyst calculations)
ROIC, net debt / EBITDA and interest coverage are not meaningful (negative EBIT and EBITDA, net cash). Cash conversion cycle is not meaningful (inventory written to nil; receivables nil at FY2025). FY2022–FY2023 ratios computed in USD.
Commentary — trends, inflections and drivers
Revenue. Reported sales have never exceeded ~US$0.4M / A$0.61M. The FY2023 peak reflected software licences from early US and Australian partners (e-Lōvu clinics onboarded 221 mothers in 2023) and Australian trials. FY2024 revenue fell 40% in AUD terms as the new management team terminated or wound down low-value arrangements and shifted to a US enterprise focus; hardware sales spiked (A$139k) on the Broward bundle. FY2025 sales fell a further 19.5%, with device sales collapsing to A$20k as kits became part of SaaS bundles, while software grew 21.7%. US revenue fell from A$327k to A$129k while Australian revenue rose from A$37k to A$164k. H1 2026 revenue was just A$38,325 (H1 2025: A$139,489) — the trough before Lee Health commercial billing, which started only on 15 September 2026.
Inflection signal. The Lee Health initial SOW of US$317,200 (≈A$0.48M at an AUD/USD rate in the mid-0.60s; analyst conversion) on its own exceeds FY2025 total sales revenue. Revenue recognition will be largely over the 12-month licence term (straight-line), so FY2026 will capture only a fraction; FY2027 should be the first year where SaaS revenue meaningfully steps up if cohorts expand.
Cost base. Operating expenses (R&D + G&A + S&M) fell from A$5.25M (FY2024) to A$3.54M (FY2025), a 33% reduction; S&M more than halved. Payroll and professional services are the dominant cost lines. H1 2026 loss before finance of A$1.60M (H1 2025: A$2.25M) and quarterly outflows of A$0.64–0.85M indicate an annualised cash burn of roughly A$2.6–3.4M (analyst calculation).
Non-cash items in FY2025. The A$629k intangible impairment (capitalised HeraBEAT development costs written to nil) and A$381k inventory write-down inflate the loss; the A$399k IIA revaluation gain offsets part. Management's note explicitly argues the market capitalisation reflects the value of the IP — a candid admission that the balance sheet no longer carries the technology.
Balance sheet and funding. The Group has no bank debt; the Meytar related-party loan was fully repaid in 2025. Equity funding is the sole source of capital; issued capital has risen from US$16.5M (start 2022) to A$41.4M (end 2025), with shares on issue up roughly sixfold from ~188M (start 2022) to ~1.16B (mid-2026). Net assets per share were 0.09 cents at 31 Dec 2025 and 0.22 cents at 30 Jun 2026 (NTA per security per Appendix 4E / half-year report).
Going concern. BDO's FY2023 report included a material uncertainty paragraph (FY2023 AR note 1(c)), and William Buck notes the FY2024 opinion likewise contained a going-concern material uncertainty paragraph. The FY2025 William Buck opinion as reviewed identifies key audit matters (IIA royalty liability; revenue contracts) and does not report a material uncertainty paragraph in the sections retrieved; the directors' declaration states reasonable grounds to believe debts can be paid. Investors should treat funding risk as live regardless.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Ownership | Function |
|---|---|---|---|
HeraMED Limited | Australia | Parent | Listed holding company, corporate and Australian commercial activity |
Hera Med Ltd ("HeraMED Israel") | Israel | 100% | Original operating company; R&D heritage; holder of IIA grant obligations |
HeraMED US Inc. ("HeraMED USA") | USA | 100% | US commercial operations (Lee Health, Philips channel) |
HeraMED Europe BV | Belgium | 100% (formed 2025) | European platform; activity not yet material |
Product Lines
| Product line (USD K) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Software revenue (USD K) | — | 204.8 | 399.1 |
Sale of goods (USD K) | — | 14.1 | 3.8 |
Total sales revenue (USD K) | 83.7 | 218.9 | 402.9 |
Product Lines (FY2023–FY2025)
| Product line (AUD K) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Software revenue (AUD K) | — | 225.0 | 273.8 |
Sale of goods (AUD K) | — | 139.3 | 19.6 |
Total sales revenue (AUD K) | 606.2 | 364.3 | 293.4 |
Government grant income (AUD K) | — | 116.9 | 138.2 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Software share of sales (%) | 93.6 | 99.0 | 61.8 | 93.3 |
Goods share of sales (%) | 6.4 | 1.0 | 38.2 | 6.7 |
Software YoY growth, local presentation currency (%) | — | 94.8 | — | 21.7 |
Total sales YoY growth, local presentation currency (%) | 161.6 | 84.0 | -39.9 | -19.5 |
Income Statement and Per-Share Data
| Metric (USD K) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Revenue (USD K) | 83.7 | 218.9 | 402.9 |
Cost of sales (USD K) | — | 78.3 | 161.0 |
Gross profit (USD K) | — | 140.6 | 241.9 |
R&D expense (USD K) | — | 758.1 | 1,405.7 |
G&A expense (USD K) | — | 1,244.4 | 1,678.3 |
Selling & marketing (USD K) | — | 497.8 | 1,125.2 |
Depreciation & amortisation (USD K) | — | 358.4 | 441.1 |
Share-based payments (USD K) | — | 462.8 | 24.0 |
Operating loss (USD K) | — | -3,180.9 | -4,432.4 |
EBITDA (USD K) | — | -2,822.5 | -3,991.3 |
Convertible note fair-value cost (USD K) | — | -1,415.9 | 0 |
Pre-tax loss (USD K) | -5,710 | -4,880.7 | -4,502.8 |
Net loss (USD K) | -5,710 | -4,880.7 | -4,502.8 |
Basic EPS (USD cents) | — | -2.3 | -1.7 |
Diluted EPS (USD cents) | — | -2.3 | -1.7 |
Dividends per share (USD) | 0 | 0 | 0 |
Income Statement and Per-Share Data (FY2023–FY2025)
| Metric (AUD K) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Sales revenue (AUD K) | 606.2 | 364.3 | 293.4 |
Government grant income (AUD K) | — | 116.9 | 138.2 |
Total revenue incl. grants (AUD K) | 606.2 | 481.2 | 431.6 |
R&D expense (AUD K) | — | 1,335.8 | 1,027.9 |
G&A expense (AUD K) | — | 2,691.2 | 1,959.2 |
Selling & marketing (AUD K) | — | 1,222.4 | 551.6 |
Depreciation & amortisation (AUD K) | — | 326.2 | 143.9 |
Impairment of intangibles (AUD K) | — | 0 | 629.4 |
Impairment of inventory (AUD K) | — | 0 | 381.1 |
Provision for doubtful debts (AUD K) | — | 0 | 94.9 |
Share-based payments (AUD K) | — | 357.0 | 119.0 |
Gain on IIA liability revaluation (AUD K) | — | 0 | 398.5 |
Operating loss (AUD K) | -6,669.3 | -5,451.4 | -4,129.8 |
EBITDA reported (AUD K) | — | -5,125.2 | -3,986.0 |
EBITDA adjusted excl. impairments and IIA gain (AUD K) | — | -5,125.2 | -3,374.0 |
Pre-tax loss (AUD K) | -6,775.2 | -5,490.6 | -4,131.6 |
Net loss (AUD K) | -6,775.2 | -5,490.6 | -4,131.6 |
Basic EPS (AUD cents) | — | -1.03 | -0.39 |
Diluted EPS (AUD cents) | — | -1.03 | -0.39 |
Dividends per share (AUD) | 0 | 0 | 0 |
Weighted average shares (millions) | — | 531.7 | 1,070.2 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Gross margin (%) | 64.2 | 60.0 | — | — |
Operating margin (%) | -1,453 | -1,100 | -1,496 | -1,408 |
EBITDA margin (%) | -1,289 | -991 | -1,407 | -1,359 |
Net margin (%) | -2,230 | -1,118 | -1,507 | -1,408 |
Balance Sheet
| Metric (USD K) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Cash & equivalents (USD K) | 3,559.0 | 2,616.6 | 723.3 |
Total current assets (USD K) | — | 3,043.0 | 1,313.8 |
Intangible assets (USD K) | — | 1,038.2 | 648.4 |
Total assets (USD K) | — | 4,156.6 | 2,014.4 |
Borrowings – related-party Meytar loan, current (USD K) | — | 178.2 | 177.9 |
Long-term debt (USD K) | — | 0 | 0 |
IIA grant liability total (USD K) | — | 556.2 | 551.6 |
Total current liabilities (USD K) | — | 790.2 | 1,027.6 |
Total liabilities (USD K) | — | 1,295.0 | 1,547.7 |
Total equity (USD K) | -106.0 | 2,861.6 | 466.7 |
Working capital (USD K) | — | 2,252.8 | 286.2 |
Net debt (USD K; negative = net cash) | — | -2,438.4 | -545.4 |
Balance Sheet (FY2023–H1 2026)
| Metric (AUD K) | FY2023 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|
Cash & equivalents (AUD K) | 1,061.9 | 3,128.6 | 1,370.7 | 2,928.0 |
Total current assets (AUD K) | — | 3,676.5 | 1,448.8 | — |
Inventories (AUD K) | — | 374.8 | 0 | — |
Intangible assets (AUD K) | — | 732.9 | 0 | — |
Goodwill (AUD K) | 0 | 0 | 0 | — |
Total assets (AUD K) | — | 4,484.2 | 1,491.0 | — |
Short-term borrowings (AUD K) | — | 82.1 | 0 | — |
Long-term borrowings (AUD K) | 0 | 0 | 0 | — |
IIA grant liability total (AUD K) | — | 733.9 | 282.4 | — |
Total current liabilities (AUD K) | — | 1,054.1 | 322.5 | — |
Total liabilities (AUD K) | — | 1,713.1 | 560.0 | — |
Total equity (AUD K) | 686.0 | 2,771.1 | 931.0 | 2,528.5 |
Working capital (AUD K) | — | 2,622.3 | 1,126.3 | — |
Net debt (AUD K; negative = net cash) | — | -3,046.5 | -1,370.7 | — |
Accumulated losses (AUD K) | — | -46,330.2 | -44,183.8 | — |
Issued capital (AUD K) | — | 38,933.2 | 41,446.9 | — |
Cash Flow
| Metric (USD K) | FY2022 | FY2023 |
|---|---|---|
Operating cash flow (USD K) | -2,560.3 | -3,796.5 |
Capex incl. capitalised development (USD K) | -690.8 | -1.4 |
Free cash flow (USD K) | -3,251.1 | -3,797.9 |
Net equity proceeds (USD K) | 2,641.7 | 2,121.2 |
Financing cash flow (USD K) | 2,538.8 | 2,020.0 |
Dividends paid (USD K) | 0 | 0 |
Buybacks (USD K) | 0 | 0 |
Cash Flow (FY2024–FY2025)
| Metric (AUD K) | FY2024 | FY2025 |
|---|---|---|
Receipts from customers (AUD K) | 607.6 | 0 |
Receipts from government grants (AUD K) | 0 | 138.2 |
Operating cash flow (AUD K) | -4,814.4 | -3,657.5 |
Capex (AUD K) | 0 | 0 |
Free cash flow (AUD K) | -4,814.4 | -3,657.5 |
Net equity proceeds (AUD K) | 7,082.8 | 1,979.4 |
Net borrowings (AUD K) | -204.7 | -68.9 |
Financing cash flow (AUD K) | 6,878.1 | 1,910.5 |
Dividends paid (AUD K) | 0 | 0 |
Buybacks (AUD K) | 0 | 0 |
Key Financials
| Metric (AUD K) | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|
Net operating cash outflow (AUD K) | -690 | -851 | -638 |
Closing cash (AUD K) | 1,370.7 | 3,145 | 2,928 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Current ratio (x) | 3.85 | 1.28 | 3.49 | 4.49 |
Debt / equity – borrowings only (x) | 0.06 | 0.38 | 0.03 | 0 |
Debt-like / equity incl. IIA (x) | 0.26 | 1.56 | 0.29 | 0.30 |
ROE on average equity (%) | — | -274 | — | -223 |
ROA on average assets (%) | — | -147 | — | -138 |
Asset turnover on average assets (x) | — | 0.13 | — | 0.10 |
R&D / sales (%) | 346 | 349 | 367 | 350 |
Revenue by Region
| Region (USD K) | FY2022 | FY2023 |
|---|---|---|
United States (USD K) | 68.3 | 199.8 |
Australia (USD K) | 128.1 | 186.2 |
Israel (USD K) | 22.5 | 16.9 |
Total (USD K) | 218.9 | 402.9 |
Revenue by Region (FY2024–H1 2026)
| Region (AUD K) | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|
United States (AUD K) | 327.2 | 129.2 | — |
Australia (AUD K) | 37.2 | 164.2 | — |
Israel (AUD K) | 0 | 0 | — |
Total (AUD K) | 364.3 | 293.4 | 38.3 |
Revenue by Region (%) and Region Margins & Growth (%)
| Metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
US share of revenue (%) | 49.6 | 89.8 | 44.0 |
Australia share of revenue (%) | 46.2 | 10.2 | 56.0 |
Israel share of revenue (%) | 4.2 | 0 | 0 |
US YoY growth (%) | 192.5 | — | -60.5 |
Australia YoY growth (%) | 45.4 | — | 341.9 |
Valuation Snapshot
| Metric | Value | Source / note |
|---|---|---|
Latest retrieved price | ~A$0.035–0.042 (late Jul–Sep 2026) | InvestSMART; Investing.com (A$0.037 on 2 Aug 2026) |
52-week range | A$0.016 – A$0.055 | Investing.com (Aug 2026) |
1-year return | +208% to +300% | Investing.com (+208%, Aug 2026); Stockopedia (+300%) — sources differ on measurement date |
3-year return | Strongly negative | — |
5-year return | Strongly negative | — |
Since IPO | ~-92% (stoxray, at A$0.02 in an earlier period) | Aggregator |
Share Price
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Placement issue price (AUD) | 0.13 | 0.07 | 0.02 | 0.012 | 0.04 |
Valuation Multiples
| Multiple | HeraMED | Note |
|---|---|---|
Market cap | ~A$43M | Consistent with TipRanks A$42.83M |
Enterprise value | ~A$40M | Market cap less A$2.93M cash (30 Jun 2026); no debt |
EV / Sales (FY2025) | ~137x | A$0.293M sales |
EV / Sales (annualised Lee SOW only) | ~83x | A$0.48M approximate annual contract value (analyst conversion) |
P/E | n/m | Loss-making |
EV / EBITDA | n/m | Negative EBITDA |
P/B (30 Jun 2026 net assets A$2.53M) | ~17x | — |
Share Count (millions)
| Metric (millions of shares) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Shares on issue at year end (millions) | 188.2 | 242.7 | 321.3 | 875.6 | 1,070.2 |
Weighted average shares (millions) | 178.5 | 214.1 | 260.5 | 531.7 | 1,070.2 |
Analyst Conclusions
Management guidance
No financial guidance. Qualitative outlook (16 Sep 2026): finalise Lee Health implementation planning, clinic onboarding schedules and Epic integration; apply the health-system qualification framework to the direct US pipeline and the Philips channel; pursue Rural Health Transformation Program opportunities; update shareholders on deployment progress.
Consensus growth expectations
No meaningful consensus exists (single unattributed target of A$0.11; no published revenue or EPS estimates).
Bull case
-
Pilot-to-commercial conversion is now proven. Lee Health moved from a six-month pilot to paid deployment with an SOW worth more than the company's entire FY2025 sales; with ~2,000 active pregnancies at Lee, cohort expansion alone could lift revenue several-fold without new logos.
-
Philips can industrialise distribution. An expanded agreement would put HeraCARE in front of Philips' US health-system relationships, potentially compressing the sales cycle that has historically stalled the company.
-
Operating leverage on a lean base. Quarterly cash burn has fallen to ~A$0.64M while the product is deployment-ready with Epic integration; incremental SaaS revenue at software-like margins could narrow losses quickly, and current cash covers roughly four quarters at the June-quarter burn rate (analyst calculation, before Lee receipts).
Bear case
-
Revenue is still immaterial and lumpy. H1 2026 revenue was A$38k; the Lee SOW is recognised over 12 months, and the company's history (Broward, FemBridge, e-Lōvu, GPEx) shows initial deals that did not scale into recurring growth.
-
Dilution is structural. Shares rose roughly sixfold in four years and ~176M options are outstanding; with A$2.9M cash and no guidance, another raise within 12 months is likely, capping per-share upside.
-
Valuation already discounts success. At ~A$40M EV the stock trades on >80x even the annualised Lee contract; any delay in Phase 2 ramp, Epic integration or the Philips expansion could trigger de-rating, while the Philips agreement can be terminated on 30 business days' notice.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| By 31 Oct 2026 | Q3 FY26 Appendix 4C | First Lee commercial receipts; cash balance; burn |
| Q4 2026 | Lee Health Epic integration and clinic onboarding | Number of mothers enrolled vs 200 initial licences; reorder of additional cohorts |
| Late 2026 – 2027 | Expanded Philips commercial agreement | Binding terms, exclusivity, revenue share, named health systems |
| Late 2026 – 2027 | Second US health-system contract | Evidence the Lee playbook is repeatable |
| Feb 2027 | FY2026 Annual Report | Revenue recognition of Lee SOW; auditor going-concern language |
| 2,027 | Capital raising | Price relative to A$0.04 Jan-2026 placement; investor quality |
| Ongoing | Rural Health Transformation Program awards | State-level procurement including maternal RPM |
| Ongoing | AI products from RMIT/Digital Health CRC | Productisation and regulatory pathway |
| Ongoing | Broward Health renewal | Retention signal for the 2024 cohort |
Analyst verdict
HeraMED has spent most of its listed life as a technology in search of a business model. Between 2018 and 2024 it cycled through consumer device sales, MOUs, small pilots across four continents, two founders' departures and a collapse in its share price to around one cent, while losses consistently ran at ten to fifteen times revenue. The question for investors in late 2026 is whether the reset under Anoushka Gungadin has genuinely changed that pattern or merely refreshed the narrative.
The evidence now leans, cautiously, toward genuine change. The company has narrowed to a single, coherent proposition — per-mother, 12-month SaaS for US health systems, with the HeraBEAT device bundled rather than sold — and it has achieved something it never previously managed: a structured pilot at a large US system with published, strong KPIs, followed by board-level approval of paid deployment and Epic integration. The Philips relationship adds a credible route to scale. Simultaneously, management has cut the cash burn by more than half and cleared the balance sheet of legacy debt and capitalised IP.
Yet the financial reality remains stark. FY2025 sales were A$293k, H1 2026 revenue was A$38k, and the A$2.9M June cash balance funds roughly a year of operations. The ~A$40M enterprise value already prices in material expansion at Lee and conversion of the Philips channel, and the capital structure — over a billion shares plus a large option overhang — means further dilution is the base case.
Our synthesis: HeraMED is a high-risk, binary, execution-driven micro-cap. The next two to three quarterly reports — enrolment numbers at Lee, reorders beyond the initial 200 licences, an expanded Philips contract and a second named US system — will determine whether this becomes a scalable SaaS story or another chapter of promising pilots. Position sizing should reflect a meaningful probability of both outcomes.
Source list (primary unless noted)
-
HeraMED Limited, Annual Report for the year ended 31 December 2025 and Appendix 4E (27 Feb 2026) — bulletin.webull.com mirrors of ASX filings
-
HeraMED Limited, Annual Report for the year ended 31 December 2024 (28 Feb 2025) — announcements.asx.com.au/asxpdf/20250228/pdf/06g45zt4qm84nj.pdf
-
HeraMED Limited, Annual Report for the year ended 31 December 2023 (28 Mar 2024) — announcements.asx.com.au/asxpdf/20240328/pdf/0620ffqhd7sxbl.pdf
-
HeraMED Limited, Half-Year Report to 30 June 2026 and Appendix 4D (Aug 2026) — bulletin.webull.com mirror
-
ASX announcements: 29 Oct 2024 (Q3 FY24 4C); 26 Nov 2024 (Metronomic LOI); 25 Nov 2025 (Philips); 27 Nov 2025 (Lee Health pilot); 27 Jan 2026 (placement); 30 Jan 2026, 30 Apr 2026, 31 Jul 2026 (Appendix 4C); 14 Jul 2026 (Lee Phase 1); 16 Sep 2026 (Lee Health full-scale expansion) — announcements.asx.com.au
-
Secondary: InvestSMART (announcement summaries, price data); Kalkine Media and ShareCafe (Q2 FY26 coverage); InvestorPA (Philips summary); Healthcare IT News (Gold Coast trial); TipRanks, Stockopedia, Simply Wall St, Investing.com, StockAnalysis, Google Finance, Parqet, stoxray, IBISWorld, MarketScreener, Motley Fool Australia, Deakin University (biography)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Holdings (31 Dec 2025 / FY2025 AR) |
|---|---|---|---|---|---|
Tim Chapman | Non-Executive Chairman | NED 11 Mar 2024; Chair 20 Jun 2024 | 25+ years in financial services and corporate advisory (IPOs, placements, RTOs, M&A); boards of remote-care companies; Clarity Capital (lead manager on 2023 placement); director of InteliCare Holdings (ASX: ICR) | BCom | 5,277,778 shares; 5,000,000 options at year end (13.17M at start; 8.17M expired) |
Anoushka Gungadin | Managing Director & CEO | Joined Jul 2022 (Strategic Partnerships ANZ); CEO Apr/May 2024; MD 20 Jun 2024 | Founding CEO of Australia India Chamber of Commerce; ex-CEO Duke of Edinburgh's Award Australia (Vic); 10 years heading finance and client accounts for Gide (law firm) in Beijing; Deakin University council member; TiE Women Australian lead | BSc (economics), MBA (Melbourne Business School) | 5,850,000 options; 15,800,000 performance rights (2,633,860 vested and exercised Mar 2026) |
David Hinton | Non-Executive Director | 21 Aug 2018 | Former CFO and Company Secretary of Empired Limited and Amcom Telecommunications; independent audit committee member, Australian Institute of Marine Science | B.Bus, FCA, GAICD | 430,000 shares; 3,000,000 options |
Dr Sharon Richardson Howell | Non-Executive Director; Chair of Advisory Board | 17 Oct 2025 | 20+ years in US health plans and health systems; former Chief Performance Officer, Centene Corporation; operates through Huntington Hill Ventures | PhD (Bayes, City of London), MBA (UC Berkeley), MSc (Harvard Medical School), BSc (USC), FACHE | 2,200,003 shares; 2,000,000 options |
Executive Leadership Team
| Name | Title | Appointed | Notes |
|---|---|---|---|
Anoushka Gungadin | MD & CEO | 2024 | See above |
Cameron Jones | CFO & Company Secretary | Co Sec 9 Apr 2024 | Associated with Bio101 (email domain in ASX releases) |
Jeff Garibaldi | Chief Growth Officer (US) | 2025 | Experience scaling digital health solutions across US health systems |
Vivek Krishnan | Chief Technology Officer | 2025 | Platform scalability |
Dr Mandy Khario (spelled "Kharia" in Chairman's letter) | Chief Clinical Transformation Officer & Chief Medical Officer | 2025 | Clinical adoption and outcomes |
Nova Taylor | Joint Company Secretary | 31 Jul 2026 | Replaced Stephanie Vipond |
Directors' Remuneration
| Director | Salary/fees | Leave provision | Super/benefits | Cash bonus | Other | Share-based | Total | % performance-based |
|---|---|---|---|---|---|---|---|---|
Tim Chapman | 50,000 | 0 | 0 | 0 | 100,000 (consulting: IR and capital raising) | 0 | 150,000 | 0 |
Anoushka Gungadin | 313,390 | 38,687 | 29,966 | 33,793 | 0 | 97,516 | 513,352 | 25.58 |
David Hinton | 44,743 | 0 | 5,257 | 0 | 0 | 0 | 50,000 | 0 |
Sharon Howell | 18,730 | 0 | 0 | 0 | 0 | 6,313 | 25,043 | 25.21 |
Total KMP | 426,863 | 38,687 | 35,223 | 33,793 | 100,000 | 103,829 | 738,395 | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 Jan / 20 Apr 2023 | Tal Slonim (co-founder) moves to NED then resigns | Founder exit |
3 Jul 2023 | Ron Weinberger becomes Executive Chairman | Commercialisation reset |
8 Nov 2023 | David Groberman (co-founder CEO) resigns; outsourced CFO appointed | Founder exit amid funding stress |
17 Jan 2024 | Emily Slade resigns | Board contraction |
11 Mar 2024 | Doron Birger resigns; Tim Chapman joins | Capital-markets orientation |
9 Apr 2024 | Ido Toronchik (CFO) ceases; Cameron Jones Co Sec | Finance function relocated to Australia |
1 May 2024 | Ron Weinberger resigns | Leadership transition |
20 Jun 2024 | Gungadin MD & CEO; Chapman Chair | New leadership |
| 2025 | CGO, CTO, CMO appointed | US commercial and clinical build |
17 Oct 2025 | Sharon Howell joins Board | US payer/provider expertise |
31 Jul 2026 | Co Sec change (Vipond → Taylor) | Administrative |
Competitive Landscape
Competitor Detail
| Sub-market | Competitor | Ownership | Relative positioning vs HeraMED |
|---|---|---|---|
Virtual maternity / women's-health platforms (US) | Maven Clinic | Private (venture-backed) | Employer/payer-funded virtual clinic at far greater scale; does not rely on a proprietary device |
| — | Babyscripts | Private | Closest US analogue: OB RPM platform with BP cuffs and remote monitoring sold to health systems |
| — | Pomelo Care | Private | Payer-focused virtual maternity care with clinical services |
| — | Ovia Health (Labcorp) | Owned by Labcorp | Consumer app and employer benefits; data scale |
| — | Wildflower Health, others | Private | Medicaid-focused maternity engagement |
Remote fetal monitoring devices | Nuvo Group (INVU) | — | FDA-cleared wearable remote fetal/maternal monitoring — more clinically comprehensive (NST-type) than a Doppler |
| — | Bloomlife | Private | Wearable contraction/fetal monitoring |
| — | Raydiant Oximetry | Private | Intrapartum fetal oximetry (adjacent) |
In-hospital fetal monitoring incumbents | Philips (Avalon) | NYSE/Euronext listed | Partner and potential competitor; dominant in hospital fetal monitoring |
| — | GE HealthCare (Corometrics; acquired Monica Healthcare 2017) | Nasdaq listed | Incumbent with wireless fetal monitoring; could build home pathway |
General IDR Mn / virtual-care platforms | — | Private / corporate | Multi-condition RPM vendors that can add obstetric pathways |
Consumer fetal dopplers | Various low-cost brands | Private | Price competition; TGA reclassification removed many from the Australian home market |
Peer Comparison FY2025
| Metric | HeraMED (FY2025) | Philips (FY2024) | GE HealthCare (FY2024) |
|---|---|---|---|
Revenue | A$0.29M sales | ~€18.0bn | ~US$19.7bn |
Revenue growth | -19.5% | — | — |
Operating margin | -1,408% | — | — |
R&D intensity | 350% of sales | — | — |
Relevance | Specialist maternity SaaS + device | Partner; hospital fetal monitoring incumbent | Hospital fetal monitoring incumbent |



